T-CELL LYMPHOMA MARKET ANALYSIS

T-cell lymphoma is a type of blood cancer which arises from unregulated growth and multiplication of T-cell lymphocytes present in the immune system of the human body. T-cell lymphoma is of two major types: peripheral T-cell lymphoma and T-cell lymphoblastic lymphoma. Peripheral T-cell lymphoma can be of various types such as cutaneous T-cell lymphoma, intestinal T-cell lymphoma, Angio-immuno-blastic T-cell lymphoma, anaplastic large cell lymphoma, follicular T-cell lymphoma, and others. The cause of T-cell lymphomas is unknown in most cases, however some of the risk factors associated with occurrence of T-cell lymphoma include viral infections such as Epstein-Barr virus or medical conditions such as coeliac disease. T-cell lymphoma can be diagnosed with the help of a tissue biopsy, blood cell counts, PET (positron emission tomography) scan, CT (computed tomography) scan, MRI (magnetic resonance imaging) scan, and others. There are various treatments available for T-cell lymphoma such as chemotherapy, radiotherapy, immunotherapy, anti-viral therapy, stem cell transplantation, and others.

The global T-cell lymphoma market is estimated to be valued at US$ 1,627.1 million in 2021 and is expected to exhibit a CAGR of 9.8% over the forecast period (2021-2028).

Figure 1. Global T-cell Lymphoma Market Share (%), By Region, 2021

To learn more about this report, request sample copy

The increasing incidence of T-cell lymphoma is expected to drive the growth of the global T-cell Lymphoma market over the forecast period.

For instance, according to an article published by the Cancer Causes Control: CCC journal in May 2019, it is estimated that non-Hodgkin lymphoma (NHL) ranks amongst the top 10 most common types of cancer with around 510,000 new cases reported globally in 2018. The same source also implies that a slight increase in incidence of NHL would be observed in the near future in several areas of the globe such as Asia, Latin America, and others. T-cell lymphoma is a type of NHL, thus growing incidence of NHL is expected to have a positive impact on global T-cell lymphoma market.

Figure 2. Global T-cell Lymphoma Market Value (US$ Mn), By Therapy Type, 2021

To learn more about this report, request sample copy

The increasing research and development activities for the development of novel therapeutics for the treatment of T-cell lymphoma is expected to drive the market growth over the forecast period.

Market players are focused on thorough research in the field of T-cell lymphoma in order to develop newer and improved therapies for the treatment of T-cell lymphoma. Manufacturers in the global T-cell lymphoma market are engaged in obtaining regulatory approvals for their T-cell lymphoma treatment therapies.

For instance, in May 2020, Takeda Pharmaceutical Company Limited, a Japan based pharmaceutical company, received approval from China’s National Medical Products Administration (NMPA) for its injection ADCETRIS (brentuximab vedotin) indicated for treatment of patients with relapsed or refractory systemic Anaplastic Large Cell Lymphoma (a type of T-cell lymphoma).

Global T-cell Lymphoma Market – Impact of Coronavirus (COVID-19) Pandemic

Coronavirus (COVID-19) outbreak was first reported on December 31, 2019, in Wuhan, China. The World Health Organization declared COVID-19, as pandemic on March 11, 2020. According to the Coronavirus (COVID-19) Weekly Epidemiological Update by the World Health Organization, over 256,480,022 cases and 5,145,002 deaths due to coronavirus (COVID-19) were reported till November 21, 2021, across the globe.

The COVID-19 pandemic and lockdown in various countries across the globe has negatively impacted the financial status of businesses across all sectors. The COVID-19 pandemic has impacted the entire supply chain of the healthcare industry mainly due to strict lockdown in several regions. Likewise, COVID-19 pandemic is expected to have a negative impact on global T-cell lymphoma market over the forecast period, owing to disruption in cancer treatment services and halt of clinical trials related to treatment of cancer. For instance, according to a report published by the World Health Organization in July 2020, around 42% of the countries around the world have disrupted services for cancer treatment in lieu of COVID-19 pandemic.

Global T-cell Lymphoma Market Restraint

The side effects of chemotherapy drugs used in the treatment of T-cell lymphoma are the factors that are expected to hinder growth of the global T-cell lymphoma market over the forecast period. For instance, according to data provided by the American Cancer Society as of May 2020, chemotherapy drugs are generally associated with side effects such as fatigue, hair loss, anemia (low red blood cell counts), nausea and vomiting, appetite changes, constipation, diarrhea, and others.

Key Players

Major players operating in the global T-cell lymphoma market include F. Hoffmann-La Roche Ltd, Biocryst Pharmaceuticals Inc., Bristol-Myers Squibb Company, Kyowa Kirin Co., Ltd., Genmab A/S, Seagen Inc., GlaxoSmithKline plc., Johnson and Johnson Private Limited, Elorac, Acrotech Biopharma, Merck and Co. Inc., Novartis AG, SHIONOGI & Co., Ltd., Spectrum Pharmaceuticals Inc., and Bausch Health Companies Inc.